Characteristics | Frequency | % |
---|---|---|
Primary tumour site | ||
Mouth | 14 | 25.5 |
Oropharynx | 17 | 30.9 |
Larynx | 16 | 29.1 |
Hypopharynx | 2 | 3.6 |
Salivary glands | 5 | 9.1 |
Unknown | 1 | 1.8 |
Tumour size (TNMa) | ||
T1 | 8 | 14.5 |
T2 | 10 | 18.2 |
T3 | 10 | 18.2 |
T4 | 17 | 30.9 |
T4a | 5 | 9.1 |
Not informed | 5 | 9.1 |
Lymph node involvement (TNMa) | ||
N0 | 25 | 45.5 |
N1 | 14 | 25.5 |
N2a | 10 | 18.2 |
N2b | 2 | 3.6 |
N3 | 3 | 5.5 |
Not informed | 1 | 1.8 |
Clinical stage | ||
I | 3 | 5.5 |
II | 8 | 14.5 |
III | 17 | 30.9 |
IV | 20 | 36.4 |
IVa | 7 | 12.7 |
Histopathological diagnosis | ||
Squamous cell carcinoma | 47 | 85.5 |
Others | 8 | 14.5 |
Oncological treatment | ||
Radiotherapy | 5 | 9.1 |
Radiotherapy and surgery | 18 | 32.7 |
Radiotherapy and chemotherapy | 18 | 32.7 |
Radiotherapy, surgery, and chemotherapy | 14 | 25.5 |
Post-treatment period (months) | ||
8 - 18 | 16 | 29.1 |
19 - 36 | 19 | 34.5 |
37 - 54 | 11 | 20 |
55 - 72 | 9 | 16.4 |
Dose (Gy) | ||
≥ 22 < 50.5 | 4 | 7.3 |
≥ 50.5 < 64 | 20 | 36.4 |
≥ 64 ≤ 70.2 | 31 | 56.4 |
aTNM, as proposed by the International Union against Cancer (UICC). Source: https://www.uicc.org/resources/tnm
|